Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
HRID 315생성일: 2026년 10월 24일
8-Chloro-4,6-dimethyl-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydropyrido[3,2-f][1,4]oxazepine → 4,6-Dimethyl-N-(5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydropyrido[3,2-f][1,4]oxazepin-8-amine
https://huagongshe.com/ko/reaction/315
참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | 8-Chloro-4,6-dimethyl-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydropyrido[3,2-f][1,4]oxazepine | HCID 57512860 | — |
| 반응물 | 5-(4-Methyl-1H-imidazol-1-yl)pyridin-2-amine | HCID 57512861 | — |
| 시약 | Cesium carbonate | HCID 10796 | — |
| 촉매 | 2-(Dicyclohexylphosphino)biphenyl | HCID 2734216 | — |
| 촉매 | Palladium (II) acetate | HCID 4144353 | — |
| 용매 | 1,2-Dimethoxyethane | HCID 8071 | — |
| 생성물 | 4,6-Dimethyl-N-(5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydropyrido[3,2-f][1,4]oxazepin-8-amine | HCID 57512825 | 15.45% |
반응 단계
To 8-chloro-4,6-dimethyl-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydropyrido[3,2-f][1,4]oxazepine (300 mg, 0.51 mmol) in DME (4 mL) were 5-(4-methyl-1H-imidazol-1-yl)pyridin-2-amine (89 mg, 0.51 mmol), cesium carbonate (249 mg, 0.76 mmol), 2-(Dicyclohexylphosphino)biphenyl (17.84 mg, 0.05 mmol) and Palladium acetate (11.43 mg, 0.05 mmol) added. The reaction was heated to 110°C for 3*90min. The solids were filtered of and washed with DCM and IPA and discarded. The solvents were evaporated and the crude product was purified using first flash chromatography, 0-7% MeOH in DCM and the prepHPLC yielding 4,6-dimethyl-N-(5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydropyrido[3,2-f][1,4]oxazepin-8-amine (34.0 mg, 15.45 %)
출처 및 근거
| 출처 데이터셋 | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-6df914594aae4a42ba5b1bcb65424482 |
|---|
| 출처 메모 | 750 AstraZeneca ELN dataset |
|---|